Clinical Trial Update: A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5 [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of two malaria vaccine candidates (ChAd63 RH5 alone and with MVA RH5) targeting Plasmodium falciparum malaria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Plasmodium Falciparum Malaria

Drugs mentioned

• ChAd63 RH5
• MVA RH5

Snippet

Sponsor: University of Oxford | Conditions: Malaria, Plasmodium Falciparum | Phase 1 | Status: COMPLETED